Awa Sarr (Dr Reynolds group, School of medicine) attended the annual Commercial Training Event for PhD students organised by Medical Research Scotland (Perth, the 19 and 20 April 2016). This event promotes university and industrial partnership.
She presented a poster of her research project entitled: “Resistance mechanisms to Gemcitabine and Acelarin in pancreatic cancer”.
This project is a collaboration between the University of Saint-Andrews and the pharmaceutical company Nucana Ltd. It aims at identifying genes and cellular pathways involved in the pancreatic cancer cell resistance to Gemcitabine (current standard treatment) and its analogue Acelarin (Nucana) treatment using the CRISPR/Cas9 system.